Molecular biomarker in prostate cancer: The role of CpG island hypermethylation

Patrick J. Bastian, S Yegnasubramanian, Ganesh S. Palapattu, Craig G. Rogers, Xiaohui Lin, Angelo Michael Demarzo, William G Nelson

Research output: Contribution to journalArticle

Abstract

CpG island hypermethylation may be one of the earliest somatic genome alterations to occur during the development of multiple cancers. Recently, aberrant methylation patterns for different tumors have been reported. We present a comprehensive review of the literature describing the role of CpG island hypermethlytion of DNA from prostatic tissue and bodily fluids from men with prostate cancer. We reviewed the literature to evaluate CpG island hypermethylation in tissue and bodily fluids of men with primary and metastatic prostate cancer. Additionally, we reviewed the literature with respect to CpG island hypermethylation patterns in other urological malignancies.Using modern analytic methods, CpG island hypermethylation detection can be achieved. In men with prostate cancer, correlations between specific gene regulatory region hypermethylation analyses and Gleason score, pathologic stage and tumor recurrence have been demonstrated. CpG island hypermethylation may serve as a useful molecular biomarker for the detection and diagnosis of patients with prostate cancer.

Original languageEnglish (US)
Pages (from-to)698-708
Number of pages11
JournalEuropean Urology
Volume46
Issue number6
DOIs
StatePublished - Dec 2004

Fingerprint

CpG Islands
Prostatic Neoplasms
Biomarkers
Neoplasms
Neoplasm Grading
Nucleic Acid Regulatory Sequences
Methylation
Genome
Recurrence
DNA
Genes

Keywords

  • CpG island
  • DNA methylation
  • Epigenetics
  • Gluthatione S-transferase
  • GSTP1
  • Hypermethylation
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Molecular biomarker in prostate cancer : The role of CpG island hypermethylation. / Bastian, Patrick J.; Yegnasubramanian, S; Palapattu, Ganesh S.; Rogers, Craig G.; Lin, Xiaohui; Demarzo, Angelo Michael; Nelson, William G.

In: European Urology, Vol. 46, No. 6, 12.2004, p. 698-708.

Research output: Contribution to journalArticle

Bastian, Patrick J. ; Yegnasubramanian, S ; Palapattu, Ganesh S. ; Rogers, Craig G. ; Lin, Xiaohui ; Demarzo, Angelo Michael ; Nelson, William G. / Molecular biomarker in prostate cancer : The role of CpG island hypermethylation. In: European Urology. 2004 ; Vol. 46, No. 6. pp. 698-708.
@article{452a47944f164d2da9e2402aee1e29df,
title = "Molecular biomarker in prostate cancer: The role of CpG island hypermethylation",
abstract = "CpG island hypermethylation may be one of the earliest somatic genome alterations to occur during the development of multiple cancers. Recently, aberrant methylation patterns for different tumors have been reported. We present a comprehensive review of the literature describing the role of CpG island hypermethlytion of DNA from prostatic tissue and bodily fluids from men with prostate cancer. We reviewed the literature to evaluate CpG island hypermethylation in tissue and bodily fluids of men with primary and metastatic prostate cancer. Additionally, we reviewed the literature with respect to CpG island hypermethylation patterns in other urological malignancies.Using modern analytic methods, CpG island hypermethylation detection can be achieved. In men with prostate cancer, correlations between specific gene regulatory region hypermethylation analyses and Gleason score, pathologic stage and tumor recurrence have been demonstrated. CpG island hypermethylation may serve as a useful molecular biomarker for the detection and diagnosis of patients with prostate cancer.",
keywords = "CpG island, DNA methylation, Epigenetics, Gluthatione S-transferase, GSTP1, Hypermethylation, Prostate cancer",
author = "Bastian, {Patrick J.} and S Yegnasubramanian and Palapattu, {Ganesh S.} and Rogers, {Craig G.} and Xiaohui Lin and Demarzo, {Angelo Michael} and Nelson, {William G}",
year = "2004",
month = "12",
doi = "10.1016/j.eururo.2004.07.022",
language = "English (US)",
volume = "46",
pages = "698--708",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Molecular biomarker in prostate cancer

T2 - The role of CpG island hypermethylation

AU - Bastian, Patrick J.

AU - Yegnasubramanian, S

AU - Palapattu, Ganesh S.

AU - Rogers, Craig G.

AU - Lin, Xiaohui

AU - Demarzo, Angelo Michael

AU - Nelson, William G

PY - 2004/12

Y1 - 2004/12

N2 - CpG island hypermethylation may be one of the earliest somatic genome alterations to occur during the development of multiple cancers. Recently, aberrant methylation patterns for different tumors have been reported. We present a comprehensive review of the literature describing the role of CpG island hypermethlytion of DNA from prostatic tissue and bodily fluids from men with prostate cancer. We reviewed the literature to evaluate CpG island hypermethylation in tissue and bodily fluids of men with primary and metastatic prostate cancer. Additionally, we reviewed the literature with respect to CpG island hypermethylation patterns in other urological malignancies.Using modern analytic methods, CpG island hypermethylation detection can be achieved. In men with prostate cancer, correlations between specific gene regulatory region hypermethylation analyses and Gleason score, pathologic stage and tumor recurrence have been demonstrated. CpG island hypermethylation may serve as a useful molecular biomarker for the detection and diagnosis of patients with prostate cancer.

AB - CpG island hypermethylation may be one of the earliest somatic genome alterations to occur during the development of multiple cancers. Recently, aberrant methylation patterns for different tumors have been reported. We present a comprehensive review of the literature describing the role of CpG island hypermethlytion of DNA from prostatic tissue and bodily fluids from men with prostate cancer. We reviewed the literature to evaluate CpG island hypermethylation in tissue and bodily fluids of men with primary and metastatic prostate cancer. Additionally, we reviewed the literature with respect to CpG island hypermethylation patterns in other urological malignancies.Using modern analytic methods, CpG island hypermethylation detection can be achieved. In men with prostate cancer, correlations between specific gene regulatory region hypermethylation analyses and Gleason score, pathologic stage and tumor recurrence have been demonstrated. CpG island hypermethylation may serve as a useful molecular biomarker for the detection and diagnosis of patients with prostate cancer.

KW - CpG island

KW - DNA methylation

KW - Epigenetics

KW - Gluthatione S-transferase

KW - GSTP1

KW - Hypermethylation

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=8444220925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8444220925&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2004.07.022

DO - 10.1016/j.eururo.2004.07.022

M3 - Article

C2 - 15548435

AN - SCOPUS:8444220925

VL - 46

SP - 698

EP - 708

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 6

ER -